tbuckley/cabot-search huggingface dataset:
Mobilization and Chemosensitization of AML with the CXCR4 Antagonist Plerixafor (AMD3100): A Phase I/II Study of AMD3100+MEC in Patients with Relapsed or Refractory Disease.
Authors: Geoffrey L. Uy, Michael P. Rettig, Kyle M. McFarland, Lindsay M. Hladnik, Shashikant Kulkarni, Camille N. Abboud, Amanda F. Cashen, Keith Stockerl-Goldstein, Ravi Vij, Peter Westervelt, John F. DiPersio
Journal: Blood (2008)
A Structure-Function Analysis Revealed Histidine in the Transmembrane Domain of Human Thrombopoietin Receptor Is Essential for a Novel Non-Peptidyl Thromobopoietin Mimetics, NIP-004, To Induce Signaling for Cellular Proliferation.
Authors: Akiko Yamane, Atsushi Miyamura, Takanori Nakamura, Norihisa Ishiwata, Katsuaki Miyaji, Nobutomo Tsuruzoe, Yasuo Ikeda, Yoshitaka Miyakawa
Journal: Blood (2005)
ATIM-28. A PHASE 1A/1B, MULTI-CENTER, OPEN-LABEL DOSE FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF THE PLEIOTROPIC PATHWAY MODIFIER CC-122 ADMINISTERED ORALLY TO PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM) AND OTHER BRAIN TUMORS
Authors: Matteo Simonelli, Juan Sepulveda, Alba Brandes, Jean-Charles Soria, John Edenfield, Victor Moreno, Jaime Gallego Pérez-Larraya, Carolyn Britten, Timothy F. Cloughesy, Maria Martinez Garcia, Carme Balana, Patrick Hagner, Yan Li, Xin Wei, Anita Gandhi, Michael Pourdehnad, Jose Antonio Lopez Martin, Armando Santoro, Kent Shih
Journal: Neuro-Oncology (2016)

CC-122 is a novel cereblon binding agent with multiple biological activities including potent immunomodulatory and anti-angiogenic effects. Following establishment of oral CC-122 3mg daily (QD) as the maximum tolerated dose (Blood 122:2905 2013), patients with CNS tumors were enrolled in an expansion cohort. As of Jan. 13, 2016, 47 patients with relapsed/refractory GBM and other brain tumors were enrolled: GBM (n=39), grade IV oligodendroglioma (n=1), grade III anaplastic oligoastrocytoma (1) grade II-III astrocytomas (n=4) and PCNSL (n=2). CC-122 was well tolerated at 3 mg QD (n=28), therefore, further dose escalation was explored in additional patients (n=19) at 4mg, 5mg or 6mg given either QD or on a 5/7days schedule. There were no DLTs, however, dose reduction (n=1) and interruptions (n=8) due to AEs were observed. The most common (≥ 5%) grade 3/4 AEs were neutropenia (10.6%), asthenia (6.4%) and general deterioration (6.4%). Drug-related serious AEs included febrile neutropenia, tumor hemorrhage, increase intracranial pressure, pulmonary embolism, interstitial lung disease, and acute respiratory distress syndrome (ARDS). AEs led to discontinuation in 10.6% of patients. 32 patients were evaluable for efficacy as of the cutoff date. The median PFS for patients was 58 days (Min-Max: 17-295, 95% CI: 50-111), while 21% of patients were progression-free at 6 months. CC-122 treatment resulted in a median increase from baseline of 86%, 133% and 165% in activated and memory cytotoxic T cells and activated helper T cells (all P<0.05), respectively, at Cycle 1 Day 15 in peripheral blood. CC-122 also activated T cells ex vivo as measured by increased levels of IFNg (131%) and IL-2 (685%) compared to baseline (both P<0.05). Preliminary CC-122 PK data suggest dose proportional increase in exposure in GBM patients. CC-122 is well tolerated. PK/PD analyses with correlation to clinical response are ongoing.
αIIb(R990W), a Constitutive Activating Mutation of Integrin αIIbβ3, Knock-in Mice Show Macrothrombocytopenia with Impairment of Platelet Function
Authors: Kazunobu Kiyomizu, Hirokazu Kashiwagi, Shinji Kunishima, Fumiaki Banno, Hisashi Kato, Youichiro Morikawa, Seiji Tadokoro, Koichi Kokame, Shigenori Honda, Toshiyuki Miyata, Yuzuru Kanakura, Yoshiaki Tomiyama
Journal: Blood (2014)
Next Generation Amplicon Sequencing of Immunoglobulin Heavy Chain Gene Rearrangaments for Minimal Residual Disease (MRD) Stratification in Childhood Acute Lymphoblastic Leukemia (ALL): A Comparison with Classical qPCR-Based Technique
Authors: Michaela Kotrova, Katerina Muzikova, Ester Mejstrikova, Michaela Novakova, Violeta Bakardjieva-Mihaylova, Fiser Karel, Jan Stuchly, Christiane Pott, Monika Bruggemann, Stary Jan, Jan Trka, Eva Fronkova
Journal: Blood (2014)
Desferrioxamine Administration Post Allogeneic Stem Cell Transplantation Reduces the Relapse Risk and Improves the Disease Free Survival.
Authors: Panayotis Kaloyannidis, Evangelia Yannaki, Aikaterini Mpitzioni, Ioannis Batsis, Despina Mallouri, Dimitrios Bartzoudis, Ioanna Sakellari, Achilles Anagnostopoulos
Journal: Blood (2008)
Postgrafting Immunosuppression with Prolonged Mycophenolate Mofetil (MMF) and Truncated Cyclosporine (CSP) Failed To Reduce the Incidence of Graft-Versus-Host Disease (GVHD) after Unrelated Donor Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning.
Authors: Frederic Baron, Brenda M. Sandmaier, Barry Storer, Michael Maris, Amelia Langston, Dietger W. Niederwieser, Effie Petersdorf, Wolfgang Bethge, Richard T. Maziarz, Peter McSweeney, Michael Pulsipher, James C. Wade, Thomas Chauncey, Judith Shizuru, Ann Woolfrey, David G. Maloney, Rainer F. Storb
Journal: Blood (2006)
Intracranial Hemorrhage (ICH) in Patients (pts) with Newly Diagnosed Leukemia: Incidence and Effect on Outcome.
Authors: Yasuhiro Oki, Elias Jabbour, Hagop Kantarjian, Elihu Estey, Jorge E. Cortes, Stefan Faderl, Sherry Pierce, Xian Zhou, B. Nebiyou Bekele, Guillermo Garcia-Manero
Journal: Blood (2004)
A retrospective analysis of cisplatin and S-1 chemotherapy for 5 patients with advanced / recurrent urachal carcinoma
Authors: Tetsuya Urasaki, Yoichi Naito, Nobuaki Matsubara, Mai Onomura, Mariko Masumoto, Masaoki Sasaki, Ako Hosono, Yoshinobu Komai, Yasuyuki Sakai, Hirofumi Mukai
Journal: Annals of Oncology (2015)
Why Are Prospective Longitudinal Studies Needed in Preterm Behavioral Epigenetic Research?—Reply
Authors: Saroj Saigal, Ryan J. Van Lieshout, Louis A. Schmidt
Journal: JAMA Pediatrics (2016)

In Reply We thank Provenzi et al for their insightful suggestions with regard to using prospective longitudinal studies, such as ours,1 to examine the effects of preterm birth and neonatal intensive care unit–related stress on the programming of health and disease in later life.
O064 : Gut-liver axis derangement due to lack of inflammasome activity leads to visceral obesity and nash development
Authors: L. Agostinelli, C. Riclicki, E. Mingarelli, C. Saponaro, M. Gaggini, E. Buzzigoli, I. Pierantonelli, S. Saccomanno, C. Pinto, L. Trozzi, A. Benedetti, S. De Minicis, M. Marzioni, A. Gastaldelli, G. Svegliati-Baroni
Journal: Journal of Hepatology (2015)
Gene Expression Profiling and FLT3 Status Correlate with Outcome in De Novo Acute Myeloid Leukemia (AML) with Normal Karyotype: Results of Children’s Oncology Group (COG) Study POG #9421.
Authors: Norman Lacayo, Soheil Meshinchi, Susana Raimondi, Chitra Saraiya, Maureen O’Brien, Ronald Yu, Dejan Juric, Myron Chang, Cheryl Willman, Robert Tibshirani, Yaddanapudi Ravindranath, Branimir Sikic, Howard Weinstein, Gary Van Houten Dahl
Journal: Blood (2005)
Cerebral Artery Velocity in Patients with β-Thalassemia Intermedia Compared to β-Thalassemia Major Using Transcranial Doppler Ultrasonography,
Authors: Mehran Karimi, Sezaneh Haghpanah, Abdolhamid Shariat, Nahid Ashjazadeh, Masoume Nazeri, Sajad Emami, Amin Abolhasani Foroughi, Peyman Petramfar, Ehsan Yaghoubi, Manijeh Lak
Journal: Blood (2011)
Autologous Tumor Combined with a GM-CSF-Secreting Cell Line Vaccine (GVAX®) Following Autologous Stem Cell Transplant (ASCT) in Multiple Myeloma.
Authors: Ivan Borrello, Barbara Biedrzycki, Nicole Sheets, Beena George, Frederick Racke, Kathy Loper, Kimberly Noonan, Amy Donnelly, Kristen Hege, Hyam Levitski
Journal: Blood (2004)
Acadesine Inhibits Proliferation and Induces Apoptosis In Multiple Myeloma Cells, and Synergizes with Standard of Care Antimyeloma Agents
Authors: Susana Hernández-García, Mercè de Frias, Clara Campàs, Bruno Paiva, Enrique M. Ocio, Jesús F. San Miguel, Atanasio Pandiella
Journal: Blood (2010)
Treatment with JNJ-26483327 (Pan Her/Src/VEGFR-3 kinase inhibitor) Prolongs Survival of Mice Engrafted with Systemic Human Acute Myeloid Leukemia
Authors: Nathaniel C. Doro, Deepika Lal, Peter King, Eddy Freyne, Tim Perera, Eunice S. Wang
Journal: Blood (2008)
Long-Term Survival and Late Deaths in 2-Year Survivors of Myeloablative Allogeneic Hematopoietic-Cell Transplantation for Hematologic Disorders.
Authors: John R. Wingard, Navneet S. Majhail, Ruta Bajorunaite, Zhiwei Wang, Kathleen A. Sobocinski, David Jacobsohn, Mohamed L Sorror, J. Douglas Rizzo, Brian J. Bolwell, Gérard Socié
Journal: Blood (2009)
Immunotherapy with Cytokine Induced Killer Cells in Solid and Hematopoietic Tumors: Preliminary Data.
Authors: Paola Olioso, Raffaella Giancola, Maria Di Riti, Patrizia Accorsi, Antonio Spadano, Dino Natale, Roberto Rossetti, Paolo Di Bartolomeo, Antonio Iacone
Journal: Blood (2005)
Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure
Authors: Michael R. Zile, Brian L. Claggett, Margaret F. Prescott, John J.V. McMurray, Milton Packer, Jean L. Rouleau, Karl Swedberg, Akshay S. Desai, Jianjian Gong, Victor C. Shi, Scott D. Solomon
Journal: Journal of the American College of Cardiology (2016)

Natriuretic peptides (NP) have prognostic value in heart failure (HF), although the clinical importance of changes in NP from baseline is unclear.The authors assessed whether a reduction in N-terminal pro-B-type NP (NT-proBNP) was associated with a decrease in HF hospitalization and cardiovascular mortality (primary endpoint) in patients with HF and reduced ejection fraction, whether treatment with sacubitril/valsartan reduced NT-proBNP below specific partition values more than enalapril, and whether the relationship between changes in NT-proBNP and changes in the primary endpoint were dependent on assigned treatment.In PARADIGM-HF (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial), baseline NT-proBNP was measured in 2,080 patients; 1,292 had baseline values >1,000 pg/ml and were reassessed at 1 and 8 months. We related change in NT-proBNP to outcomes.One month after randomization, 24% of the baseline NT-proBNP levels >1,000 pg/ml had fallen to ≤1,000 pg/ml. Risk of the primary endpoint was 59% lower in patients with a fall in NT-proBNP to ≤1,000 pg/ml than in those without such a fall. In sacubitril/valsartan-treated patients, median NT-proBNP was significantly lower 1 month after randomization than in enalapril-treated patients, and it fell to ≤1,000 pg/ml in 31% versus 17% of patients treated with sacubitril/valsartan and enalapril, respectively. There was no significant interaction between treatment and the relationship between change in NT-proBNP and the subsequent risk of the primary endpoint.Patients who attained a significant reduction in NT-proBNP had a lower subsequent rate of cardiovascular death or HF hospitalization independent of the treatment group. Treatment with sacubitril/valsartan was nearly twice as likely as enalapril to reduce NT-proBNP to values ≤1,000 pg/ml. (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial) [PARADIGM-HF]; NCT01035255.).
Aortic Cross-Sectional Area/Height Ratio and Outcomes in Patients With a Trileaflet Aortic Valve and a Dilated Aorta
Authors: Ahmad Masri, Vidyasagar Kalahasti, Lars G. Svensson, Eric E. Roselli, Douglas Johnston, Donald Hammer, Paul Schoenhagen, Brian P. Griffin, Milind Y. Desai
Journal: Circulation (2016)

In patients with a dilated proximal ascending aorta and trileaflet aortic valve, we aimed to assess (1) factors independently associated with increased long-term mortality and (2) the incremental prognostic utility of indexing aortic root to patient height.We studied consecutive patients with a dilated aortic root (≥4 cm) that underwent echocardiography and gated contrast-enhanced thoracic aortic computed tomography or magnetic resonance angiography between 2003 and 2007. A ratio of aortic root area over height was calculated (cm2/m) on tomography, and a cutoff of 10 cm2/m was chosen as abnormal, on the basis of previous reports. All-cause death was recorded.The cohort comprised 771 patients (63 years [interquartile range, 53-71], 87% men, 85% hypertension, 51% hyperlipidemia, 56% smokers). Inherited aortopathies, moderate to severe aortic regurgitation, and severe aortic stenosis were seen in 7%, 18%, and 2%, whereas 91% and 54% were on β-blockers and angiotensin-converting enzyme inhibitors, respectively. Aortic root area/height ratio was ≥10 cm2/m in 24%. The Society of Thoracic Surgeons score and right ventricular systolic pressure were 3.3±3 and 31±7 mm Hg, respectively. At 7.8 years (interquartile range, 6.6-8.9), 280 (36%) patients underwent aortic surgery (76% within 1 year) and 130 (17%) died (1% in-hospital postoperative mortality). A lower proportion of patients in the surgical (versus nonsurgical) group died (13% versus 19%, P<0.01). On multivariable Cox proportional hazard analysis, aortic root area/height ratio (hazard ratio, 4.04; 95% confidence interval [CI], 2.69-6.231) was associated with death, whereas aortic surgery (hazard ratio, 0.47; 95% CI, 0.27-0.81) was associated with improved survival (both P<0.01). For longer-term mortality, the addition of aortic root area/height ratio ≥10 cm2/m to a clinical model (Society of Thoracic Surgeons score, inherited aortopathies, hypertension, hyperlipidemia, medications, aortic regurgitation, and right ventricular systolic pressure), increased the c-statistic from 0.57 (95% CI, 0.35-0.77) to 0.65 (95% CI, 0.52-0.73) and net reclassification index from 0.17 (95% CI, 0.02-0.31) to 0.23 (95% CI, 0.04-0.34), both P<0.01. Of the 327 patients with aortic root diameter between 4.5 and 5.5 cm, 44% had an abnormal aortic root area/height ratio, of which 78% died.In patients with dilated aortic root and trileaflet aortic valve, a ratio of aortic root area to height provides independent and improved stratification for prediction of death.
Potential Role of Enhanced Cytokinemia and Endotoxemia on the Decreased Activity of Plasma ADAMTS13 in Patients with Alcoholic Hepatitis.
Authors: Masatoshi Ishikawa, Masahito Uemura, Tomomi Matsuyama, Masanori Matsumoto, Masao Fujimoto, Hiromichi Ishizashi, Seiji Kato, Chie Morioka, Tatsuhiro Tsujimoto, Toshiyuki Kitazawa, Hidehito Kawaratani, Yoshihiro Fujimura, Hiroshi Fukui
Journal: Blood (2008)
In Vitro Exposure to DL-4 Increases the in Vitro and In Vivo T-Lymphopoietic Potential of CB Derived CD34+ Progenitor Cells
Authors: Christian Reimann, Liliane Liliane Dal-Cortivo, Emmanuelle M. Six, Andrea Schiavo, Marina Cavazzana-Calvo, Isabelle Andre-Schmutz
Journal: Blood (2011)
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PRELIMINARY REPORT OF THE ITALIAN TRIAL
Authors: A Tedeschi, M Coscia, D Rossi, F Ricci, G D'Arena, E Orlandi, Vb Petrizzi, L Scarfo, C Vitale, E Vismara, G Gaidano, E Morra, M Massaia, M Montillo
Journal: Annals of Oncology (2011)
Appropriate Use of High-Sensitivity Cardiac Troponin Levels in Patients With Suspected Acute Myocardial Infarction
Authors: Andrew R. Chapman, Anoop S. V. Shah, Nicholas L. Mills
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Immunotherapy with Long-Lived Anti-CD20 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human B Cell Lines and of Circulating and Lymphoid B Cells in Monkeys: A Potential Therapy for B Cell Lymphomas and Leukemias
Authors: Seung Y. Chu, Sung-Hyung Lee, Rumana Rashid, Hsing Chen, Emily W. Chan, Sheryl Phung, Erik Pong, Nancy A. Endo, Yvonne Miranda, Christine Bonzon, Irene W.L. Leung, Umesh S. Muchhal, Gregory L. Moore, Matthew J. Bernett, David E. Szymkowski, John R. Desjarlais
Journal: Blood (2014)
Automated Pre-Classification of Anemia Based on the Results of a Routine Automated Hematology System.
Authors: Alexander Kratz, Laura Rubattu, Micheline Maier-Redelsperger, Giovanni Amendola, Paolo Danise, Giuseppe d’Onofrio, Gina Zini, Hans van Duijnhoven, Virginie Siguret, Isabelle Gouin-Thibault, Maria Gioia, Enrico Cillari, Anthony Ermens, Gianni Carandina, Therese Cynober, Chantal Fossat, Jean-Francois Lesesve, Salignac Sylvain
Journal: Blood (2005)
Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia
Authors: Irene M. Ghobrial, Ranjit Banwait, Tiffany Poon, Federico Campigotto, Erica N Boswell, Stacey Chuma, Janet Kunsman, Amanda Donovan, Meghan Bagshaw, Diane Warren, Kenneth C. Anderson, Paul G. Richardson, Edie Weller, Timothy J. Murphy, Jeffrey Matous
Journal: Blood (2011)
Predicting Non-Responders to Immunotherapy Treatments through Simulation of NGS Information
Authors: Kim A. Brogden, Carol L. Fischer, Amber M. Bates, Emily A. Lanzel, Maria Paula Gomez Hernandez, Christopher N. Treinen, Erica N. Recker, Prashant R. Nair, Karthik Sundara, Vishwas Joseph, Taher Abbasi, Shireen Vali
Journal: Blood (2015)
Clinical outcome of triple-negative primary breast cancer in older women: Comparison with their younger counterparts.
Authors: K. Cheung, B. M. Syed, A. R. Green, D. A. L. Morgan, I. O. Ellis
Journal: Journal of Clinical Oncology (2011)

1057 Background: It is generally believed that triple-negative (ER-/PR-/HER2-) primary breast cancers have poor prognosis. Following surgery, adjuvant chemotherapy is currently the only treatment that could potentially improve survival. On the other hand, the absolute benefit of adjuvant chemotherapy in older women appears small and its precise value remains to be proven. As such its use tends to be very limited in this population. Methods: Over 36 years (1973−2009), 2,000+ older (≥70 years) women with early operable primary breast cancer were managed in a dedicated clinic. Of these 127 patients with triple negative invasive carcinoma (defined as ER/PR = 0% positive cells, HER2 = 1+ or 2+ on IHC and CISH negative) underwent primary surgery and had good quality tumour samples available for tissue microarray (TMA) analysis using indirect immunohistochemistry. The results were compared with their younger (<70 years) counterparts from a previously characterised, consecutive series (N=1,809) treated in the same unit (1986–1998). Among them, there were 342 patients who had triple negative tumors. Results: At a median follow-up of 46 months (longest=204) (≥70 years) and 119 months (longest=135) (<70 years), the results are shown in the table. Conclusions: Despite not having received adjuvant chemotherapy, the older series had clinical outcome similar to the younger patients almost half of which had chemotherapy. This may be due to other biomarkers (in addition to ER/PR/HER2) which have different patterns in these age groups influencing prognosis. The place of adjuvant chemotherapy in the treatment of these patients has yet to be identified. Treatment pattern <70 years ≥70 years With adjuvant chemotherapy 149 (47.0%) 0 Without adjuvant chemotherapy 168 (53.0%) 127 (100%) Outcome at 5 years P value Breast cancer-specific survival 73% 79% 0.39 Local recurrence 10% 14% 0.16 Regional recurrence 11% 14% 0.40 Metastases 30% 27% 0.56
Autologous Stem Cell Transplantation for Multiple Myeloma in Patients with Reduced Renal Function: A Matched Set Comparison.
Authors: Shaji Kumar, Martha Lacy, Angela Dispenzieri, Suzanne Hayman, Nelson Leung, Vincent Rajkumar, Steven Zeldenrust, John Lust, Philip Greipp, Dennis Gastineau, Morie Gertz
Journal: Blood (2006)
Comparison of Umbilical Cord Blood Derived Mononuclear Cells and Endothelial Generating Cells in Response to Ischemia in the Murine Hind-Limb Injury Model.
Authors: Marcie R. Finney, Vincent J. Pompili, Nicholass G. Greco, Matthew J. Joseph, Daniel G. Winter, Jason Banks, Shyam Bhakta, Margaret Kozik, Laura R. Fanning, Ying Huang, Mary J. Laughlin
Journal: Blood (2005)
Feasibility study of emergency intervention for vascular injury outside the hospital
Authors: Ming Liang, Jing-Jing Rong, Jing-Yang Sun, Xiao-Zeng Wang, Fei Li, Geng Wang, Yan-Chun Liang, Ya-Ling Han
Journal: Military Medical Research (2016)

Minimally invasive surgery in the field of traumatic vascular injury diagnosis and treatment has achieved good results. This study was designed to determine whether pre-hospital emergency intervention is feasible for vascular injury in a field intervention cabin under the condition of war or a disaster site.Different types of animal experiments of vascular injury intervention were performed in a field intervention cabin. Treatment capacity was evaluated by data collection, including duration of surgery, clinical evaluation, image clarity, and equipment handling. Environmental adaptability and mobility were evaluated by maneuverability and long-distance mobility.A total of 56 surgeries (7 types) were performed in the field intervention cabin. Digital subtraction angiography (DSA) had good imaging performance. A total of 4800 km of long-distance mobility was performed, and all the equipment operated normally without any equipment failure. We participated in the medical service maneuver twice. The cabin unfolded and worked properly. There was no equipment damage during the medical service maneuver.Use of a field intervention cabin under the conditions of war or disaster is feasible for pre-hospital emergency intervention of vascular injury.
Activation of Nuclear Factor KappaB in ETV6/FLT3-Transformed Ba/F3 Cells Depends on the FLT3 Tyrosine 591.
Authors: Hoang Anh Vu, Phan Thi Xinh, Yasuhiko Kano, Takaomi Ishida, Toshiki Watanabe, Katsushi Tokunaga, Yuko Sato
Journal: Blood (2007)
Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment
Authors: Masatoshi Kudo, Franco Trevisani, Ghassan K Abou-Alfa, Lorenza Rimassa
Journal: Liver Cancer (2016)

Western and Eastern perspectives on therapeutic guidelines for hepatocellular carcinoma (HCC) have many commonalities but may also differ in certain aspects, as described in this article. In view of the limited therapeutic options for advanced HCC, evidence-based therapies are few, and thus there is a dependence on consensus-based guidelines. This article focuses on the Italian Association for the Study of the Liver guidelines and the Japanese approaches to therapy, while drawing attention to certain controversies from other academic bodies where applicable and appropriate.